Journal
THERAPEUTIC DRUG MONITORING
Volume 45, Issue 2, Pages 140-142Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FTD.0000000000001064
Keywords
isavuconazole; therapeutic drug monitoring; liver cirrhosis
Ask authors/readers for more resources
The authors present a case of a 67-year-old woman with primary biliary cirrhosis who was treated with isavuconazole for aspergillosis. Therapeutic drug monitoring was performed to determine the dose adjustments and ensure the safe and successful management of the treatment.
Background:The authors present a case of a 67-year-old woman with primary biliary cirrhosis (Child-Pugh class B) who was treated with isavuconazole for invasive pulmonary and cerebral aspergillosis. Isavuconazole treatment was initiated with the standard maintenance dose of 200 mg daily. Therapeutic drug monitoring (TDM) was performed to target trough concentrations within the desired range of 1.0-5.13 mg/L.Methods:Real-time TDM and pharmacokinetic analyses were used to determine the dose adjustments. Liver transaminases (alanine aminotransferase and gamma-glutamyl transferase) were assessed to monitor hepatotoxicity.Results:The trough plasma levels gradually increased over time up to 17.8 mg/L. TDM-guided clinical pharmacological advice was helpful to initially reduce the dose, then to temporarily suspend drug administration, and finally to calculate the correct dose that allowed for long-term treatment up to day 258. No major signs and/or symptoms of drug-related toxicity occurred, apart from a transient increase in gamma-glutamyl transferases that normalized after the drop in isavuconazole trough levels within the desired range.Conclusions:TDM-guided clinical pharmacological advice was essential for the successful and safe management of isavuconazole treatment in this patient with moderate liver dysfunction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available